tailieunhanh - báo cáo hóa học: " Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes"

Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí hóa học quốc tế đề tài : Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes | BioMed Central Health and Quality of Life Outcomes Research Fear of hypoglycaemia defining a minimum clinically important difference in patients with type 2 diabetes Tom Stargardt 1 2 Linda Gonder-Frederick3 Karl J Krobot4 and Charles M Alexander5 Address 1Health Services Management Munich School of Management Munich University Germany institute of Health Economics and Health Care Management Helmholtz Zentrum Munich Germany 3Department of Psychiatry and Neurobehavioral Sciences University of Virginia Charlottesville VA USA 4Outcomes Research MSD Sharp Dohme GMBH Haar Germany and 5Outcomes Research Merck Co Inc Whitehouse Station NJ USA Email Tom Stargardt - Stargardt@ Linda Gonder-Frederick - LAG3G@ Karl J Krobot - karl_krobot@ Charles M Alexander - charles_alexander@ Corresponding author Open Access Published 22 October 2009 Received 3 June 2009 Health and Quality of Life Outcomes 2009 7 91 doi 1477-7525-7-91 Accepted 22 October 2009 This article is available from http content 7 1 91 2009 Stargardt et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract_ Background To explore the concept of the Minimum Clinically Important Difference MID of the Worry Scale of the Hypoglycaemia Fear Survey HFS-II and to quantify the clinical importance of different types of patient-reported hypoglycaemia. Methods An observational study was conducted in Germany with 392 patients with type 2 diabetes mellitus treated with combinations of oral anti-hyperglycaemic agents. Patients completed the HFS-II the Treatment Satisfaction Questionnaire for Medication TSQM and reported on severity of